Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000734363 | SCV000862496 | uncertain significance | not provided | 2018-07-19 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001331240 | SCV001523237 | uncertain significance | Epidermolysis bullosa simplex with nail dystrophy | 2020-01-27 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Labcorp Genetics |
RCV001855810 | SCV002171987 | uncertain significance | Epidermolysis bullosa simplex 5B, with muscular dystrophy; Epidermolysis bullosa simplex, Ogna type; Epidermolysis bullosa simplex 5C, with pyloric atresia; Autosomal recessive limb-girdle muscular dystrophy type 2Q; Epidermolysis bullosa simplex with nail dystrophy | 2023-07-10 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 598067). This variant has not been reported in the literature in individuals affected with PLEC-related conditions. This variant is present in population databases (rs369798520, gnomAD 0.02%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 3694 of the PLEC protein (p.Arg3694Gln). |
Revvity Omics, |
RCV000734363 | SCV003816680 | uncertain significance | not provided | 2019-06-17 | criteria provided, single submitter | clinical testing |